tiprankstipranks
Advertisement
Advertisement

CGEM Stock Latest News

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
The FlyCullinan Therapeutics price target raised to $46 from $33 at Clear Street
5d ago
CGEM
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
PremiumCompany Announcements
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
6d ago
8K
CGEM
Cullinan Therapeutics reports CLN-978, velinotamig data
PremiumThe Fly
Cullinan Therapeutics reports CLN-978, velinotamig data
6d ago
CGEM
Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential
PremiumRatings
Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential
7d ago
CGEM
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
PremiumCompany Announcements
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
8d ago
8K
CGEM
Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained
PremiumRatingsCullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained
8d ago
CGEM
Cullinan Therapeutics presents clinical data for CLN-978
Premium
The Fly
Cullinan Therapeutics presents clinical data for CLN-978
8d ago
CGEM
Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors
Premium
Company Announcements
Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors
10d ago
CGEM
Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig
PremiumThe Fly
Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig
21d ago
CGEM
Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street
PremiumThe Fly
Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street
27d ago
CGEM
Cullinan Therapeutics receives orphan drug designation for CLN-049
PremiumThe Fly
Cullinan Therapeutics receives orphan drug designation for CLN-049
28d ago
CGEM
Cullinan Management Shares Promising Early CLN-978 Autoimmune Data
PremiumCompany Announcements
Cullinan Management Shares Promising Early CLN-978 Autoimmune Data
28d ago
8K
CGEM
Cullinan Therapeutics price target raised to $37 from $36 at Wedbush
PremiumThe FlyCullinan Therapeutics price target raised to $37 from $36 at Wedbush
1M ago
CGEM
Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)
Premium
The Fly
Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)
1M ago
CGEM
Cullinan jumps after UCB acquires Candid Therapeutics
Premium
The Fly
Cullinan jumps after UCB acquires Candid Therapeutics
1M ago
CGEM
Cullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook
PremiumRatings
Cullinan Oncology: FDA Acceptance of Zipalertinib NDA and Upcoming CLN-978 Data Underpin Buy Rating and Favorable NPV Outlook
2M ago
CGEM
Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright
PremiumThe Fly
Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright
2M ago
CGEM
Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib
PremiumThe Fly
Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib
2M ago
CGEM
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
PremiumThe Fly
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
3M ago
CGEM
GILD
Cullinan Therapeutics price target raised to $36 from $34 at Wedbush
PremiumThe FlyCullinan Therapeutics price target raised to $36 from $34 at Wedbush
3M ago
CGEM
Cullinan: Advancing Immunology and Oncology Pipeline Undervalued; Buy Rating on CLN-978 Catalysts and Strong Cash Runway
Premium
Ratings
Cullinan: Advancing Immunology and Oncology Pipeline Undervalued; Buy Rating on CLN-978 Catalysts and Strong Cash Runway
3M ago
CGEM
Cullinan Management Adopts Reduced SEC Reporting: Lower Compliance Costs, But Potential Hit to Investor Appeal and Liquidity
Premium
Company Announcements
Cullinan Management Adopts Reduced SEC Reporting: Lower Compliance Costs, But Potential Hit to Investor Appeal and Liquidity
3M ago
CGEM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >